Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 19/20 | 0.54 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.42 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18496713 | 1.00 | FOLH1 (0.54) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL18516882 | 0.88 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL18496714 | 0.88 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL18516883 | 0.88 | FOLH1 (0.64) | FOLH1RIMKLANAALAD2 | |
| SCHEMBL30340353 | 0.85 | GLP1R (0.54) | — | |
| SCHEMBL867921 | 0.84 | CAPN1 (0.47) | FOLH1 | |
| SCHEMBL867922 | 0.84 | CAPN1 (0.47) | FOLH1 | |
| SCHEMBL28567097 | 0.84 | FOLH1 (0.58) | FOLH1 | |
| SCHEMBL28567093 | 0.84 | FOLH1 (0.58) | FOLH1 | |
| SCHEMBL28567088 | 0.84 | FOLH1 (0.58) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11078166-B2 | Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| US-20190225589-A1 | TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11078166-B2 | Triazole conjugated ureas, thioureas, carbamates, and reversed carbamates for PSMA-targeted imaging agents and uses thereof | PAICS, FOLH1, UTS2R | FOLH1 2/4885RIMKLA 1026/4885NAALAD2 213/4885 |
| US-20190225589-A1 | TRIAZOLE CONJUGATED UREAS, THIOUREAS, CARBAMATES, AND REVERSED CARBAMATES FOR PSMA-TARGETED IMAGING AGENTS AND USES THEREOF | PAICS, FOLH1, UTS2R | FOLH1 2/4885RIMKLA 1026/4885NAALAD2 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.